Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Bruno T. Lins x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Objective—To determine sedative and cardiorespiratory effects of dexmedetomidine alone and in combination with butorphanol or ketamine in cats.

Design—Randomized crossover study.

Animals—6 healthy adult cats.

Procedures—Cats were given dexmedetomidine alone (10 μg/kg [4.5 mg/lb], IM), a combination of dexmedetomidine (10 μg/kg, IM) and butorphanol (0.2 mg/kg [0.09 mg/lb], IM), or a combination of dexmedetomidine (10 μg/kg, IM) and ketamine (5 mg/kg [2.3 mg/lb], IM). Treatments were administered in random order, with ≥ 1 week between treatments. Physiologic variables were assessed before and after drug administration. Time to lateral recumbency, duration of lateral recumbency, time to sternal recumbency, time to recovery from sedation, and subjective evaluation of sedation, muscle relaxation, and auditory response were assessed.

Results—Each treatment resulted in adequate sedation; time to lateral recumbency, duration of lateral recumbency, and time to recovery from sedation were similar among treatments. Time to sternal recumbency was significantly greater after administration of dexmedetomidine-ketamine. Heart rate decreased significantly after each treatment; however, the decrease was more pronounced after administration of dexmedetomidine-butorphanol, compared with that following the other treatments. Systolic and diastolic blood pressure measurements decreased significantly from baseline with all treatments; 50 minutes after drug administration, mean blood pressure differed significantly from baseline only when cats received dexmedetomidine and butorphanol.

Conclusions and Clinical Relevance—Results suggested that in cats, administration of dexmedetomidine combined with butorphanol or ketamine resulted in more adequate sedation, without clinically important cardiovascular effects, than was achieved with dexmedetomidine alone. (J Am Vet Med Assoc 2003;222:37–41)

Full access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To determine sedative and cardiorespiratory effects of romifidine alone and romifidine in combination with butorphanol and effects of preemptive atropine administration in cats sedated with romifidine-butorphanol.

Design—Randomized crossover study.

Animals—6 healthy adult cats.

Procedures—Cats were given saline (0.9% NaCl) solution followed by romifidine alone (100 µg/kg [45.4 µg/lb], IM), saline solution followed by a combination of romifidine (40 µg/kg [18.1 µg/lb], IM) and butorphanol (0.2 mg/kg [0.09 mg/lb], IM), or atropine (0.04 mg/kg [0.02 mg/lb], SC) followed by romifidine (40 µg/kg, IM) and butorphanol (0.2 mg/kg, IM). Treatments were administered in random order, with ≥ 1 week between treatments. Physiologic variables were determined before and after drug administration. Time to recumbency, duration of recumbency, time to recover from sedation, and subjective evaluation of sedation, muscle relaxation, and analgesia were assessed.

Results—Bradycardia developed in all cats that received saline solution and romifidine-butorphanol or romifidine alone. Preemptive administration of atropine prevented bradycardia for 50 minutes in cats given romifidine-butorphanol. Oxyhemoglobin saturation was significantly decreased 10 minutes after romifidine-butorphanol administration in atropinetreated cats.

Conclusions and Clinical Relevance—Results suggested that administration of romifidine alone or romifidine-butorphanol causes a significant decrease in heart rate and that preemptive administration of atropine in cats sedated with romifidine-butorphanol effectively prevents bradycardia for 50 minutes. (J Am Vet Med Assoc 2002;221: 506–510)

Full access
in Journal of the American Veterinary Medical Association